-
1 Comment
China Medical System Holdings Limited is currently in a long term uptrend where the price is trading 40.1% above its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.0.
China Medical System Holdings Limited's total revenue rose by 23.4% to $4B since the same quarter in the previous year.
Its net income has increased by 58.2% to $1B since the same quarter in the previous year.
Finally, its free cash flow grew by 141.2% to $616M since the same quarter in the previous year.
Based on the above factors, China Medical System Holdings Limited gets an overall score of 5/5.
| Exchange | HK |
|---|---|
| CurrencyCode | HKD |
| ISIN | KYG211081248 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| PE Ratio | 11.38 |
|---|---|
| Target Price | 10.8202 |
| Beta | 0.91 |
| Market Cap | 20B |
| Dividend Yield | 3.5% |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate depression. It also provides gastroenterology products, such as METOJECT, a methotrexate injection to treat severe recalcitrant disabling psoriasis and rheumatoid arthritis; LUMEBLUE, a methylthioninium chloride enteric-coated sustained-release tablets for colorectal lesion visualization; Salofalk for ulcerative colitis and Crohn's disease; Bioflor, a saccharomyces boulardii sachets for diarrhea; Combizym and Cidine for digestive enzymes; and Ursofalk, a ursodeoxycholic acid capsules to treat cholesterol gallstones. In addition, the company offers dermatology products, including ILUMETRI, a tildrakizumab injection for the treatment of plaque psoriasis; Aethoxysklerol, a polidocanol injection for sclerotherapy of various varicose veins; Hirudoid, a mucopolysaccharide polysulfate cream to treat blunt traumata; skin heling soothing product; and Hirudoid for acne-prone skin care, prevention, and enhancement of acne. Further, it provides Vmonalisa, modified sodium hyaluronate filler for mid to deep dermal implantation; augentropfen stulln mono eye drops for asthenopia; EyeOP1 glaucoma treatment device; and Elcitonin for Osteoporosis pain. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 0867.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
